Market capitalization | $109.74m |
Enterprise Value | $-171.13m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 2.94 |
EV/Sales (TTM) EV/Sales | -11.10 |
P/S ratio (TTM) P/S ratio | 7.12 |
P/B ratio (TTM) P/B ratio | 0.29 |
Sales growth (TTM) Sales growth | -0.47% |
Turnover (TTM) Turnover | $15.42m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
3 Analysts have issued a Seer Inc - Ordinary Shares - Class A forecast:
3 Analysts have issued a Seer Inc - Ordinary Shares - Class A forecast:
Mar '24 |
+/-
%
|
||
Net profit | -21 -21 |
14%
14%
|
|
Depreciation and amortization | 1.49 1.49 |
14%
14%
|
|
Share compensation | 7.58 7.58 |
13%
13%
|
|
Operating cash flow | -10 -10 |
46%
46%
|
|
Investments | 0.75 0.75 |
525%
525%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -11 -11 |
42%
42%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr., and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Omid Farokhzad |
Employees | 147 |
Founded | 2017 |
Website | www.seer.bio |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.